CNDAC is a metabolite of sapacitabine with potent antitumor activity; it exhibits inhibitory effects against HL-60 and THP-1 leukemia cell lines; it is more effective than cytarabine (ara-C) in reducing cell viability and inducing apoptosis in ara-C-resistant THP-1 cells; it induces replication-dependent DNA double-strand breaks (DSBs); it shows enhanced cytotoxicity in cells deficient in homologous recombination repair proteins (e.g., Rad51D, XRCC3, or ATM); it is under investigation for the treatment of cancers, particularly hematological malignancies.